Columbia Asset Management Maintains Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Columbia Asset Management Maintains Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Columbia Asset Management maintained its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, Holdings Channel reports. The institutional investor owned 1,780 shares of the biopharmaceutical company’s stock at the end of the third quarter. Columbia Asset Management’s holdings in Alexion Pharmaceuticals were worth $218,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Cornerstone Advisors Inc. raised its position in shares of Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares during the last quarter. Bellwether Investment Group LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth approximately $172,000. NEXT Financial Group Inc raised its position in shares of Alexion Pharmaceuticals by 37.7% in the third quarter. NEXT Financial Group Inc now owns 1,523 shares of the biopharmaceutical company’s stock worth $187,000 after buying an additional 417 shares during the last quarter. Charlemagne Capital Ltd. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth approximately $191,000. Finally, Evercore Wealth Management LLC raised its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares during the last quarter. 95.95% of the stock is owned by institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 129.23 on Friday. The firm has a market cap of $28.94 billion, a PE ratio of 78.80 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 52-week low of $109.12 and a 52-week high of $162.00. The stock has a 50 day moving average price of $128.01 and a 200-day moving average price of $126.86.

A number of equities analysts recently commented on ALXN shares. Brean Capital started coverage on Alexion Pharmaceuticals in a research note on Tuesday, October 4th. They set a “buy” rating and a $221.00 price target for the company. Credit Suisse Group reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, November 7th. Piper Jaffray Companies set a $176.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 6th. Vetr raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a research note on Monday, November 7th. Finally, Deutsche Bank AG initiated coverage on Alexion Pharmaceuticals in a research note on Thursday, November 3rd. They issued a “buy” rating and a $164.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $172.80.

In other Alexion Pharmaceuticals news, Director Leonard Bell sold 1,300 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $135.28, for a total transaction of $175,864.00. Following the completion of the sale, the director now owns 406,589 shares of the company’s stock, valued at $55,003,359.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alvin S. Parven sold 22,659 shares of the company’s stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $138.35, for a total value of $3,134,872.65. Following the sale, the director now directly owns 14,305 shares of the company’s stock, valued at approximately $1,979,096.75. The disclosure for this sale can be found here. Insiders have sold 104,852 shares of company stock valued at $14,542,657 in the last ninety days. Company insiders own 4.41% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Related posts

Leave a Comment